Want to see CRDF full AI Analyst Report?

Cardiff Oncology (CRDF) Price & Analysis

1,993 Followers

CRDF Stock Chart & Stats

$1.02

$0.02(2.30%)

At close: Jul 27 4:00 PM EDT

$1.02

$0.02(2.30%)

Day’s Range― - ―

52-Week Range$0.76 - $3.31

Previous CloseN/A

Volume462.43K

Average Volume (3M)548.93K

Market Cap

$70.95M

Enterprise Value$54.85M

Total Cash (Recent Filing)$34.52M

Total Debt (Recent Filing)$457.00K

Price to Earnings (P/E)―

Beta1.28

Next Earnings

Mar 04, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.60

Shares Outstanding77,795,250

10 Day Avg. Volume475,622

30 Day Avg. Volume548,933

Financial Highlights & Ratios

PEG Ratio0.15

Price to Book (P/B)4.14

Price to Sales (P/S)316.73

P/FCF Ratio-4.95

Enterprise Value/Market Cap0.77

Enterprise Value/Revenue107.98

Enterprise Value/Gross Profit107.98

Enterprise Value/Ebitda-1.41

Forecast

1Y Price Target

$7.50

Price Target Upside635.29% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.58

Revenue Forecast (FY)$292.14K

Bulls Say, Bears Say

Bulls Say

Low LeverageExtremely low leverage limits debt-servicing pressure and preserves financial flexibility for a development-stage biotechnology company. This gives Cardiff more room to direct available capital toward clinical programs and reduces solvency risk, although it does not remove the need for future funding.

Clinical Development ProgressProgress toward a registrational Phase 3 study represents an important advancement for onvansertib and could broaden the company’s development prospects if clinical evidence remains supportive. Prolonged treatment durations also provide meaningful ongoing data as Cardiff moves its lead program toward late-stage development.

License And Litigation ResolutionResolving the dispute removes a material legal overhang around Cardiff’s lead asset and establishes clearer development economics and collaboration terms. Defined exclusivity, royalty, milestone and governance provisions should improve planning visibility as onvansertib advances toward its planned Phase 3 program.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flow means Cardiff is consuming capital to fund research and clinical development rather than internally financing operations. Continued burn increases dependence on external funding and could constrain the pace or scope of programs if financing conditions become less favorable.

Large Losses And Minimal RevenueThe company remains firmly pre-commercial, with minimal and declining revenue unable to offset substantial operating expenses and development costs. This earnings profile limits self-funding capacity and leaves future financial performance highly dependent on successful clinical advancement and eventual commercialization.

Potential Shareholder DilutionThe expanded share authorization gives Cardiff useful funding flexibility, but it also increases the potential for substantial equity issuance while losses and cash burn persist. Financing through additional shares could support clinical programs yet dilute existing ownership and reduce per-share participation in future gains.

Cardiff Oncology News

Cardiff Oncology names Leila Alland interim chief medical officer

Cardiff Oncology (CRDF) announced the appointment of Leila Alland as interim chief medical officer. Alland is a seasoned...

3d ago

CRDF

Cardiff Oncology treatment of chronic myelomonocytic leukemia gets orphan status

Cardiff Oncology’s (CRDF) onvansertib was granted FDA orphan designation as a treatment of chronic myelomonocytic leukemia, according to...

9d ago

CRDF

Cardiff Oncology Names Interim CMO Amid Trial Progress

Cardiff Oncology ( ($CRDF) ) has shared an announcement. Cardiff Oncology expanded its capital structure on October 22,...

3d ago

CRDF

CRDF Earnings this Week: How Will it Perform?

Cardiff Oncology, Inc. (CRDF) is scheduled to report 3rd quarter earnings on 10/29/2026. Regarding Q3 estimates, Wall Street...

3d ago

CRDF

Cardiff Oncology Shareholders Approve Expanded Capital Structure

Cardiff Oncology ( ($CRDF) ) just unveiled an update. On October 22, 2026, Cardiff Oncology, Inc. held a...

8d ago

CRDF

Cardiff Oncology upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Cardiff Oncology (CRDF) to Buy from Neutral with a $9 price target The company reached...

2M ago

CRDF

Cardiff Oncology Amends Onvansertib License, Resolves Litigation

Cardiff Oncology ( ($CRDF) ) has shared an announcement. On September 14, 2026, Cardiff Oncology and Nerviano Medical...

2M ago

CRDF

Cardiff Oncology, Nerviano Medical Sciences reach settlement

Cardiff Oncology (CRDF) and Nerviano Medical Sciences announced that they have reached a settlement and amended their 2017...

2M ago

CRDF

Cardiff Oncology reports Q2 EPS (14c), consensus (16c)

Reports Q2 revenue $104,000, consensus $62,780. “The second quarter was an important period of progress for Cardiff, highlighted...

2M ago

CRDF

Cardiff Oncology downgraded to Market Perform from Outperform at William Blair

William Blair downgraded Cardiff Oncology (CRDF) to Market Perform from Outperform. Post-Q2 results, the firm said the company’s...

2M ago

CRDF

Okta upgraded, Gap downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

BSP

GAP

Take-Two, Quantum, On, Cardiff, Autodesk Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($TTWO) ), ( ($QMCO) ), ( ($ONON) ), ( ($CRDF)...

3M ago

ADSK

CRDF

CRDF Earnings this Week: How Will it Perform?

Cardiff Oncology, Inc. (CRDF) is scheduled to report 2nd quarter earnings on 07/30/2026. Regarding Q2 estimates, Wall Street...

3M ago

CRDF

Cardiff Oncology completes $10 million financing transaction

Cardiff Oncology ( ($CRDF) ) just unveiled an announcement. On July 14, 2026, Cardiff Oncology entered into agreements...

4M ago

CRDF

CRDF FAQ

What was Cardiff Oncology, Inc.’s price range in the past 12 months?

Cardiff Oncology, Inc. lowest stock price was $0.76 and its highest was $3.31 in the past 12 months.

What is Cardiff Oncology, Inc.’s market cap?

Cardiff Oncology, Inc.’s market cap is $70.95M.

When is Cardiff Oncology, Inc.’s upcoming earnings report date?

Cardiff Oncology, Inc.’s upcoming earnings report date is Mar 04, 2027 which is in 125 days.

How were Cardiff Oncology, Inc.’s earnings last quarter?

Cardiff Oncology, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.02.

Is Cardiff Oncology, Inc. overvalued?

According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cardiff Oncology, Inc. pay dividends?

Cardiff Oncology, Inc. does not currently pay dividends.

What is Cardiff Oncology, Inc.’s EPS estimate?

Cardiff Oncology, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cardiff Oncology, Inc. have?

Cardiff Oncology, Inc. has 77,795,250 shares outstanding.

What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?

Cardiff Oncology, Inc. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went up 1.672%.

Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?

Currently, no hedge funds are holding shares in CRDF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cardiff Oncology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-103.08%

Trailing 12-Months

Asset Growth

-50.71%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Cardiff Oncology (CRDF) Earnings & Revenues

Historic Earnings Reports

CRDF Stock 12 Month Forecast

Average Price Target

$7.50

▲(635.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.18,1.7815384615384615,2.3830769230769233,2.9846153846153847,3.586153846153846,4.187692307692307,4.78923076923077,5.390769230769231,5.992307692307692,6.593846153846154,7.195384615384615,7.796923076923077,8.39846153846154,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.18,1.666153846153846,2.1523076923076925,2.6384615384615384,3.1246153846153844,3.6107692307692307,4.096923076923077,4.583076923076923,5.069230769230769,5.555384615384615,6.041538461538462,6.527692307692307,7.013846153846154,{"y":7.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.18,1.5507692307692307,1.9215384615384616,2.292307692307692,2.663076923076923,3.033846153846154,3.4046153846153846,3.775384615384615,4.1461538461538465,4.516923076923077,4.887692307692308,5.258461538461538,5.6292307692307695,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.17,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.71,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.855,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >